GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ardelyx Inc (FRA:41X) » Definitions » PensionAndRetirementBenefit

Ardelyx (FRA:41X) PensionAndRetirementBenefit : €0.0 Mil (As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Ardelyx PensionAndRetirementBenefit?

Ardelyx's PensionAndRetirementBenefit for the quarter that ended in Sep. 2024 was €0.0 Mil.


Ardelyx PensionAndRetirementBenefit Historical Data

The historical data trend for Ardelyx's PensionAndRetirementBenefit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ardelyx PensionAndRetirementBenefit Chart

Ardelyx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PensionAndRetirementBenefit
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Ardelyx Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PensionAndRetirementBenefit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Ardelyx PensionAndRetirementBenefit Calculation

PensionAndRetirementBenefit is the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement.


Ardelyx Business Description

Industry
Traded in Other Exchanges
Address
400 Fifth Avenue, Suite 210, Waltham, MA, USA, 02451
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.

Ardelyx Headlines

No Headlines